RUNX1 gene expression in Egyptian acute myeloid leukemia patients: may it have therapeutic implications?

• Main Authors: Fadwa Said, Roxan E. Shafik, Naglaa M. Hassan
• Format: Article
• Language: English
• Published: SpringerOpen 2021-06-01
• Series: Egyptian Journal of Medical Human Genetics
• Subjects: Acute myeloid leukemia; RUNX1; Gene expression; Egypt
• Online Access: https://doi.org/10.1186/s43042-021-00179-4

Abstract Background Acute myeloid leukemia represents the highest percentage of all adult acute leukemia variants. Runt-related transcription factor1 (RUNX1), a transcription factor with a known tumor suppressor function, was recently reported as a tumor promoter in acute myeloid leukemia (AML). We investigated the role of RUNX1 gene expression level in Egyptian AML patients and delineated its clinical significance. Results We measured RUNX1 gene expression level using reverse transcription-quantitative polymerase chain reaction and found that the RUNX1 gene expression level was significantly higher than the control group (p < 0.001). Patients with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations had a higher expression level of RUNX1 (p = 0.023). The male patients expressed a significantly higher level of RUNX1 (p = 0.046). Conclusions The RUNX1 gene is highly expressed in Egyptian AML patients. It has a relation to FLT3-ITD, which may give a clue that patients carrying this mutation may benefit from new treatments that target RUNX1 in the future. Further studies on a larger number of patients with different ethnic groups may give a clearer vision of the therapeutic implications of a new molecular target.